Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future

Molecularly targeted agents are changing the therapeutic landscape in advanced non-small cell lung cancer. Since the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) domain, clinical investigations have focused on optimizing the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Spaans, Johanna N., Goss, Glenwood D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145253/
https://www.ncbi.nlm.nih.gov/pubmed/25221748
http://dx.doi.org/10.3389/fonc.2014.00233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145253/
https://www.ncbi.nlm.nih.gov/pubmed/25221748
http://dx.doi.org/10.3389/fonc.2014.00233

Ejemplares similares